Introduction of Real World Outcomes of Left Atrial Appendage Occlusion

↳ This is a section part of Moment: Real World Outcomes of Left Atrial Appendage Occlusion

Add this Moment to your Passport

Learn from this moment and keep it forever.
FREE
Add To Passport

Preview

Summary

Atrial fibrillation (AF), the most common arrhythmia, is associated with a significantly increased risk of morbidity and mortality due to a fivefold increase in the frequency of thromboembolic stroke.1 The gold standard treatment for the prevention of AF-related thromboembolism is oral anticoagulation (OAC), based on an individualised patient risk assessment with either the CHADS2 or the CHA2DS2-VASc score.2 However, up to 20 % of patients with AF cannot take OAC therapy,3 and there exists a considerable bleeding risk among those that can tolerate OAC: intracranial bleeding occurs in 1 % of patients taking warfarin per annum, whereas survivors of a haemorrhagic stroke are generally considered inappropriate for anticoagulation for life.4,5 In addition, OAC is associated with significant morbidity and its associated cost implications: for example, OAC-related gastrointestinal (GI) bleeding causes repeated hospitalisations and blood transfusions, and carries a mortality rate of up to 10 %.6 The HASBLED score is the most widely used tool to estimate the risk of major bleeding for patients on OAC therapy.7 Novel OACs have been shown to be either non-inferior or superior to warfarin therapy with equivalent or decreased bleeding events. Nevertheless, there remains an annual 2–3 % incidence of major bleeding.8

Add this Moment to your Passport

Learn from this moment and keep it forever.
FREE
Add To Passport

Target Audience

Learning Objectives

Loading Simple Education